Esophageal Diseases  >>  Xolair (omalizumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xolair (omalizumab) / Roche, Novartis
NCT01040598: Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model

Completed
1
19
US
Omalizumab, Xolair
O & O Alpan LLC, Genentech, Inc.
Eosinophilic Esophagitis
12/11
 

Download Options